Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD)

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00078221

Enrollment

180

Registered

2004-03-01

Start date

1999-08-31

Completion date

2005-12-31

Last updated

2008-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Degeneration

Keywords

Dry AMD, Age-related Macular Degeneration, Rheopheresis

Brief summary

AMD is a progressive disease of the retina which is nourished by a network of tiny blood vessels. There is evidence to suggest that the flow of nutrients to the retina is impaired in patients with AMD. Rheopheresis blood filtration uses blood filters that deplete excesses of large proteins, fats and other substances from the blood, improving blood flow to the macula, potentially improving vision.

Interventions

DEVICERheopheresis blood filtration

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

50 Years to 85 Years

Healthy volunteers

Yes

Inclusion criteria

* Age 50-85 * Diagnosis of Dry AMD * BCVA between 20/32 and 20/125 in at least one eye * Numerous large plaques (soft drusen) * No history of HIV, Hepatitis B or C * Elevation of certain blood factors, such as total cholesterol, fibrinogen, and IgA

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026